France's Diatos, a 2004 Fierce 15 company, is going public with an IPO designed to raise €25 million. Diatos CEO John Tchelingerian said the company is braving difficult market conditions in mounting the offering, but that institutional investors backed the move. Diatos has specialized in developing its own cancer therapies.
- here's the Dow Jones report on the IPO